Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275)

Market Cap	7.87B
Revenue (ttm)	2.05B
Net Income (ttm)	342.73M
Shares Out	587.57M
EPS (ttm)	0.58
PE Ratio	23.00
Forward PE	n/a
Dividend	0.60 (4.47%)
Ex-Dividend Date	May 29, 2024

Volume	1,612,302
Open	13.65
Previous Close	13.57
Day's Range	13.29 - 13.65
52-Week Range	11.28 - 18.35
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2024

About Guilin Sanjin Pharmaceutical

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China. The company primarily offers Guilin watermelon frost and lozenge, and Sanjin tablets under the Chinese TCM brand; and Naomaitai capsules, etc. It also produces TCM preparations. Guilin Sanjin Pharmaceutical Co., Ltd. was founded in 1967 and is headquartered in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. operates as a subsidiary of Guilin SanJin Group Co.,Ltd.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1967
• Employees: 2,615
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002275

Financial Performance

In 2023, Guilin Sanjin Pharmaceutical's revenue was 2.17 billion, an increase of 10.81% compared to the previous year's 1.96 billion. Earnings were 421.30 million, an increase of 27.85%.